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Abstract
Background: Cervical cancer is one of the most important cancers worldwide with a high incident and mortality
rate and is caused by the human papilloma virus (HPV). Among sexually active women who get infected with human
papillomavirus (HPV), a small fraction progresses to cervical cancer disease pointing to possible roles of additional risk
factors in development of the disease which include host genetic factors and other infections such as HSV-2. Since
cellular apoptosis plays a role in controlling the spread of virus-infections in cells, gene variants altering the function of
proteins involved in cell death pathways might be associated with the clearing of virus infections. Activity altering
polymorphisms in FasR (−1377G > A and -670A > G), FasL (−844 T > C) and CASP8 (−652 6 N ins/del) genes have been
shown to alter the mechanism of apoptosis by modifying the level of expression of their correspondent proteins.
In the present study, we set out to investigate the combined risks of CASP8, FasR, and FasL polymorphisms in cervical
cancer, pre-cancerous lesions, HPV infection and HSV-2 infection.
Methods: Participants were 442 South African women of black African and mixed-ancestry origin with invasive cervical
cancer and 278 control women matched by age, ethnicity and domicile status. FasR and FasL polymorphisms were
genotyped by TaqMan and CASP8 polymorphism by PCR-RFLP. The results were analysed with R using haplo.stats
software version 1.5.2.
Results: CASP8 -652 6 N del + FasR-670A was associated with a reduced risk (P = 0.019, Combined Polymorphism Score
(CPS) = −2.34) and CASP8 -652 6 N ins + FasR-1377G was associated with a marginal increased risk (P = 0.047, CPS = 1.99)
of cervical cancer among black Africans. When compared within the control group, CASP8 -652 6 N ins + FasR-1377A
showed a reduced risk (P = 0.023, CPS = −2.28) of HSV-2 infection in both black African and mixed-ancestry population.
Conclusions: Our results show that the combined risks of variants in cell death pathway genes are associated with the
cervical cancer as well as the HSV-2 infection in the black African and mixed-ancestry population.
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Background
Cervical cancer is the second most common cancer and
the highest cause of cancer related deaths across the globe.
Approximately 500, 000 new cases of cervical cancer and
nearly 300, 000 deaths (52 %) caused by cervical cancer
are reported each year making it the third most common
cancer in women of all ages worldwide. Cervical cancer is
the second most common cancer in southern Africa with
approximately 6,500 new incidents and the second highest
cause of cancer mortality with around 3000 cervical can-
cer related deaths (53 %) annually in women of all ages
[1]. Persistent infection with oncogenic types of human
papillomavirus (HPV) is the main cause of cervical cancer.
Many sexually active women become infected with HPV
during their life time but 70–90 % of the individuals posi-
tive for HPV DNA are able to clear the infection. Only a
small percentage of the women with HPV progress to de-
velop cervical cancer over their time [2]. This suggests a
possible role of additional risk factors such as, host and
viral genetic factors as well as environmental and lifestyle
factors in the development of the cancer of the cervix [3].
Herpes simplex virus type 2 (HSV-2) is a common sexu-
ally transmitted virus that causes genital infections. HSV-2
has a high prevalence rate throughout the world, more so
in the developing nations. Sub-Saharan Africa particularly
harbours a high incidence rate with more women being
affected than men [4]. HSV-2 in conjunction with HPV
has been implicated as a co-factor for cervical cancer [5].
Once inside a human cell, HSV-2 evades the immune sys-
tem by overcoming the apoptosis of the cell which is
triggered by Fas-FasL-Caspase pathway. Fas mediated cy-
tolysis plays an important role in clearing the HSV-2 from
genital epithelium [6].
Apoptosis or programmed cell death is one of the most
crucial mechanisms of the human immune system to con-
trol viral infection in human body [7]. The interaction be-
tween cell surface death receptor Fas (FasR), together with
Fas ligand (FasL) activates a caspase-cascade leading to
activation-induced cell death (AICD) that eventually leads
to apoptosis to eliminate the virus-infected cells [8, 9].
Among various caspases, caspase-8 is central to activating
the caspase-cascade [10] and plays one of the most im-
portant roles in generating apoptotic signals [9]. Therefore
functional polymorphisms in the cell death pathway genes
encoding FasR, FasL and caspase-8 might interfere with
the apoptotic process associated with the spread and
clearance of virus-infections inside human body.
The FasR and FasL genes are mapped on chromosome
10q23 and 1q23 respectively. Three functional single nu-
cleotide polymorphisms (SNPs) in these two genes (FasR-
1377G >A, FasR-670A >G and FasL-844 T > C) have been
well studied. FasR-1377G >A and FasR-670A >G poly-
morphisms disrupt the SP1 and STAT1 binding sites re-
spectively leading to reduced Fas gene expression and
decreased apoptosis [11, 12]. FasL-844 T > C is observed
to show higher basal expression that inhibits the apoptotic
activity of the FasR-FasL pathway [13]. These three SNPs
have been associated with different diseases [11, 13–24] in-
cluding cervical cancer in different populations [14, 25–30].
The other important factor in the apoptotic pathway,
caspase-8 is encoded by CASP8 gene which is mapped on
chromosome 2q33. A six nucleotide deletion of AGTAAG
at the position 652 in the promoter region of CASP8 gene
(CASP8 -652 6 N ins/del) have been well studied. This six
nucleotide deletion destroys the SP1-binding site which
reduces the caspase-8 expression and thereby decreas-
ing the apoptotic activity of the caspase-cascade [31].
This polymorphism has been associated with different
types of diseases [31–41] including cervical cancer in
different populations [31, 41].
No studies to date have attempted to find out the
combined risks of all the four polymorphisms from FasR
(−1377G > A, −670A > G), FasL (−844 T > C) and CASP8
(−652 6 N ins/del) genes on cervical cancer, HPV infec-
tion or HSV-2 infection in any population. We therefore
re-analysed our data evaluating the combined risks of
CASP8 polymorphism in the presence of both FasR and
FasL polymorphisms, on cancer of the cervix susceptibil-
ity, HPV infection and HSV-2 infection in South African
women of black African and mixed-ancestry origin.
Methods
Study participants
Participants in this study were recruited as part of a big-
ger case–control study to investigate the association of
oral contraceptives with cervical cancer [41–43] and in-
cluded 442 women with invasive cervical cancer (104
black African and 338 women of mixed-ancestry) and
278 control women (52 black African and 226 women of
mixed-ancestry) without cancer of the cervix recruited
from two previous studies from our lab that investigated
the role of FasR (FasR-1377, FasR-670) and FasL (FasL-
844) [30] and CASP8 polymorphisms (−652 6 N ins/del)
[41] on cervical cancer.
Herpes simplex virus type 2 (HSV-2) detection, high-risk
HPV type detection and papanicolau test
The detection of HSV-2 infection (by HerpeSelect 2 IgG
enzyme-linked immunosorbent serologic assay), high-
risk HPV infection (by Hybrid Capture II HPV test) and
abnormal cytology (by Papanicolaou or Pap smear test)
have been described previously [24, 43].
Clinical specimens, extraction of genomic DNA and
genotyping
The collection and storage of clinical specimens, extraction
and quantification of genomic DNA and determination of
FasR (FasR-1377: rs2234767, assay id, C_12123966_10;
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FasR-670: rs1800682, assay id, C_9578811_10), FasL (FasL-
844: rs763110, custom-designed) and CASP8 (rs3834129:–/
AGTAAG;NM_001228.4) polymorphisms have been de-
scribed previously [24, 41]. All experiments were performed
in compliance with relevant laws and institutional guide-
lines (University of Cape Town Human Research Ethics
Committee study approval number, REC REF: 075/2009)
and in accordance with the ethical standards of the Declar-
ation of Helsinki. Written informed consent was obtained
from each participant of this study.
Statistical analysis
The genotype distributions for all the polymorphisms
were tested for Hardy-Weinberg equilibrium and linkage
disequilibrium for cases and controls. Logistic regression
was used to test for correlations and associations of dif-
ferent combinations of combined genotypes (CASP8
with FasR/FasL) with cervix cancer status as well as
baseline characteristics and secondary outcomes such as
age, ethnicity, smoking status, HSV-2 and HIV infection
status in cases and controls. HPV and high-risk HPV in-
fection and abnormal cytology status test was done only
in the control group (the information for these categor-
ies were only available for the controls). Statistical ana-
lyses were done with R (the freely available environment
for graphics and statistics), using haplo.stats software
version 1.5.2 http://CRAN.R-project.org/package=haplo.-
stats. Broadly, haplo.stats uses the expectation maximisa-
tion (EM) algorithm, to calculate maximum likelihood
estimates of probabilities of haplotype pairs (one paternal,
one maternal) for each subject [44].
Results
No significant difference in age was observed between
cases and controls (P = 0.271) (Table 1). 31 % (n = 135)
cases and 40 % (n = 111) controls were tobacco smokers.
Smoking was found to be associated with the cases and
controls significantly (P = 0.01). The HSV-2 status was
known for 429 cases and 263 controls. Among cases
68 % (n = 291) were positive for HSV-2 infection while
among controls 164 (47 black African and 117 women
of mixed-ancestry) were positive for HSV-2 infection
(62 %). There was no significant difference in the HSV-2
infection between cases and controls. HIV infection sta-
tus was known for 433 cases and 263 controls. Only 5 %
of cases and 4 % of controls were HIV infected which
was not found to be significant (Table 1). HPV infection,
abnormal cytology and high-risk HPV infection status
was known only among controls. HPV infection occurred
at a frequency pf 28 % among the 170 controls who had
results, while abnormal cytology and high-risk HPV infec-
tion was positive in 13 % and 14 %, respectively, among
the 269 controls with available data Analysis of only the
controls showed a significant association (P = 0.013) be-
tween abnormal cytology and ethnicity (Table 1).
The observed genotype frequencies for all the polymor-
phisms were found to be in Hardy-Weinberg equilibrium
(HWE) except for CASP8 -652 6 N ins/del which was
slightly out of HWE (P = 0.045) in mixed-ancestry controls
[30, 41]. FasR polymorphisms (−1377 and −670) were in
strong linkage disequilibrium (LD) (P < 0.05) except in
black African controls (P = 0.078) [30]. We have previously
reported that the allele and genotype frequency distribu-
tions for FasR/FasL differ significantly between the ethnic
groups (black African and mixed-ancestry) investigated
[30]. Among all the baseline characteristics and secondary
outcomes only smoking was found to be a significant con-
founding factor for cancer of the cervix as mentioned
above. Therefore, all analyses were subsequently adjusted
for both ethnicity and smoking by including in logistic re-
gression models as covariates.
CASP8 polymorphism (CASP8 -652 6 N ins/del) was
combined with any (and all) of the FasR (−1377, −670) and
FasL (−844) polymorphisms which gave rise to 7 combina-
tions of polymorphisms (total 52 different combinations)
as shown in Additional file 1. None of the combinations
showed any significant association (P < 0.05) with cancer of
the cervix (both population combined) (Table 2). When
stratified for different populations, the mixed-ancestry
population again did not show any significant association
(P < 0.05) with the disease (Table 2). However, the black
Africans showed a marginal increased risk with
CASP8 -652 6 N ins + FasR-1377G (P = 0.047, Combined
Polymorphism Score (CPS) = 1.99) and cervical cancer
and a reduced risk with CASP8 -652 6 N del + FasR-670A
(P = 0.019, CPS = −2.34) with the same disease (CPS is
similar as a haplotype score; a positive value suggests a
positive association and a negative value suggests a nega-
tive association with the disease under investigation)
(Table 2). The combined risks of CASP8 -652 6 N del +
FasR-670A polymorphism showed a reduced risk of cer-
vical cancer even when combined with FasR-1377 and
FasL-844 polymorphisms (Table 2).
Comparing the different polymorphisms in smoking
positive and HSV-2 positive cases and controls did not
show any significant association (results not shown
here) either.
The combined risks of the polymorphisms were also in-
vestigated only within the control group, as the controls
represent the larger healthy South-African female popula-
tion, unlike the cervical cancer group that is affected by a
disease. When HSV-2 infection status was compared in the
control group for the different combinations of the poly-
morphisms, a reduced risk was found with CASP8 -652
6 N ins + FasR-1377A (P = 0.023, CPS = −2.28) and HSV-2
infection (Table 3). The combined risks of these two poly-
morphisms showed a reduced risk of HSV-2 infection even
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when combined with FasR-670 and FasL-844 polymor-
phisms (Table 3). Comparing the other parameters such as,
smoking, high-risk HPV infection and abnormal cytology
status in the control group did not yield any significant as-
sociation with any of the parameters mentioned (results
not shown here).
Discussion
The cell death pathway is one of the most essential path-
ways in human immune system. This pathway is central
to and regulates cellular apoptosis which is one of the
mechanisms by which the immune system controls in-
fections caused by pathogenic viruses [7]. Disruptions in
cell death pathway can lead to impaired apoptotic mech-
anism which may affect the ability of the immune system
to control the spread of virus-infections in cells. Three
functional polymorphisms in FasR (FasR-1377, FasR-
670) and FasL genes (FasL-844) and one in CASP8 gene
(CASP8 -652 6 N ins/del), all in cell death pathway are
known to disrupt the apoptotic mechanism by altering
the level of expression of Fas and caspase-8 proteins, re-
spectively [11–13, 31]. All the four polymorphisms have
been investigated in different types of cancers such as
breast [32, 33, 37], bladder [19, 40], lung [20, 23], squamous
cell carcinoma [15, 22], colorectal [35], pancreatic [36],
different leukaemia [11, 16], cervical [14, 25–31, 41] and
several other pathological conditions [11, 13–23, 31–41], all
presenting with conflicting results. Previously we have in-
vestigated these four polymorphisms in cervical cancer in
South African women of black African and mixed-ancestry
origin [24, 30, 41]. Comparing women with invasive cer-
vical cancer with age, ethnicity and domicile (urban/rural)
matched controls did not show any significant association
for FasR and FasL polymorphisms with cervical cancer [30].
However, a secondary analysis only in the control group
found a statistically significant association with FasR-1377A
(P = 0.008) and FasR-1377/FasR-670 AG haplotype (P =
0.0001) with reduced risk of HSV-2 infection [24]. When
CASP8 -652 6 N ins/del polymorphism was compared
between cervical cancer cases and controls no signifi-
cant association with cervical cancer was observed [41].
However, further analysis within only controls showed
an association (positive) of CASP8 -652 6 N del/del (P =
0.03) polymorphism with high-risk HPV infection (only
among black Africans) and a weak association (positive)
with abnormal cytology (P = 0.048) suggesting a suscep-
tible role for this genotype in the development of pre-
cancers but not in cervical cancer [41]. The combined
risks of all the four polymorphisms of FasR, FasL and
CASP8 on cervical cancer, HPV infection, pre-cancerous
Table 1 Distribution of characteristics of cervical cancer cases and control subjects
Characteristics Cases Controls P-value#
Black Mixed-ancestry Black Mixed-ancestry
Number of subjects 104 338 52 226
Age (years), mean ± SD 43.7 ± 9.3 45.9 ± 8.1 40.8 ± 8.9 45.5 ± 8.1 0.271
Smoking
Positive 82 53 44 67 0.012
Negative 22 285 8 159
HSV-2 infection
Infected 93 198 47 117 0.161
Non-infected 10 128 3 96
HIV infection
Infected 13 9 4 7 0.589
Non-infected 89 322 46 206
HPV infection
Infected 12 35 0.539
Non-infected 26 97
Abnormal cytology
Positive 12 23 0.013
Negative 39 195
High-risk HPV infection
Positive 7 32 0.862
Negative 44 186
#P-values were based on chi square test and for black and mixed-ancestry combined
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lesions and HSV-2 infection have not been investigated in
any population yet.
Since all the four polymorphisms play vital roles in the
cell death pathway leading to altered mechanism of cellular
apoptosis it is valuable to investigate the combined risks of
CASP8 polymorphism with any (and all) of the FasR/FasL
polymorphisms in cervical cancer, pre-cancerous lesions,
HPV infection and HSV-2 infection. None of the combina-
tions of the polymorphisms had any significant association
with cancer of the cervix in both populations combined
and also when stratified for mixed-ancestry population,
which is in accordance with our previous individual results
with FasR/FasL [30] and CASP8 polymorphisms [41].
However, when stratified among only black Africans a
new reduced risk for cervical cancer was observed with
CASP8 -652 6 N del combined with FasR-670 A allele
(P = 0.019, CPS = −2.34). In the same population, a mar-
ginal susceptible risk to cervical cancer was also observed
when CASP8 -652 6 N ins was combined with FasR-
1377 G allele (P = 0.047, CPS = 1.99). This could be due to
Table 2 Association statistics for combined polymorphisms of CASP8 (− 652 6 N ins/del), FasR-1377 (G > A), FasR-670 (A > G) and
FasL-844 (T > C) for cervical cancer cases and controls
Black Africans and Mixed Ancestry combined
Haplotype or Genotype combinations Cases, n = 442 (frequency) Controls, n = 278 (frequency) P-value (global)
CASP8 + FasR-1377 87 (49) 92 (51) 0.531
CASP8 + FasR-670 98 (50) 99 (50) 0.63
CASP8 + FasL-844 97 (50) 98 (50) 0.738
CASP8 + FasR-1377 + FasR-670 86 (48) 92 (52) 0.813
CASP8 + FasR-1377 + FasL-844 85 (48) 91 (52) 0.771
CASP8 + FasR-670 + FasL-844 95 (50) 97 (50) 0.937
CASP8 + FasR-1377 + FasR-670 + FasL-844 84 (48) 90 (52) 0.978
Among Black Africans
Combined Polymorphisms Cases, n = 104 (frequency) Controls, n = 52 (frequency) P-value (global)
CASP8 + FasR-1377 96 (66) 49 (34) 0.138 (global P)
−652 6 N ins and G (41) (28) 0.047 (CPS = 1.99)
CASP8 + FasR-670 103 (67) 51 (33) 0.028 (global P)
−652 6 N del and A (6) (19) 0.019 (CPS = −2.34)
CASP8 + FasL-844 103 (67) 51 (33) 0.1 (global P)
CASP8 + FasR-1377 + FasR-670 96 (67) 48 (33) 0.131 (global P)
−652 6 N del, G and A (6) (19) 0.019 (CPS = −2.35)
CASP8 + FasR-1377 + FasL-844 95 (66) 48 (34) 0.181 (global P)
CASP8 + FasR-670 + FasL-844 102 (67) 50 (33) 0.047 (global P)
−652 6 N del, A and C (1) (7) 0.018 (CPS = −2.36)
CASP8 + FasR-1377 + FasR-670 + FasL-844 95 (67) 47 (33) 0.115 (global P)
−652 6 N del, G, A and C (9) (7) 0.027 (CPS = −2.21)
Among Mixed-Ancestry group
Haplotypes Cases, n = 338 (frequency) Controls, n = 226 (frequency) P-value (global)
CASP8 + FasR-1377 289 (58) 208 (42) 0.747
CASP8 + FasR-670 330 (59) 225 (41) 0.966
CASP8 + FasL-844 326 (59) 222 (41) 0.909
CASP8 + FasR-1377 + FasR-670 282 (58) 207 (42) 0.971
CASP8 + FasR-1377 + FasL-844 280 (58) 204 (42) 0.924
CASP8 + FasR-670 + FasL-844 320 (59) 221 (41) 0.991
CASP8 + FasR-1377 + FasR-670 + FasL-844 275 (58) 203 (42) 0.996
P-values and Combined Polymorphism Scores (CPSs) are for test of combined polymorphism association with cervix cancer risk, adjusted for smoking and
ethnicity for total cases and controls and smoking only for stratified population groups. CPS = combined polymorphism score. Cases =Women with cancer of the
cervix, Controls = Women without cancer of the cervix
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different factors. The black Africans are a homogenous
population with well defined genetic conformation unlike
the mixed-ancestry population that carries a highly mixed
genetic makeup. It is also well known that disease suscep-
tibility varies from population to population due to vary-
ing level of genetic markers present in various population.
When the combined risks of the polymorphisms were
investigated only in the controls, a reduced risk for HSV-2
infection was observed with CASP8 -652 6 N ins + FasR-
1377A. This is in consistence with our previous results
[24] that showed a reduced risk for HSV-2 infection with
FasR-1377A allele alone in the control group as men-
tioned above. CASP8 promoter polymorphism individu-
ally have also been associated with reduced risk of
cutaneous melanoma, lung, esophageal, gastric, breast,
colorectal and cervical cancer [31, 34] in different
population even though in our own population we
found an increased risk of this polymorphism with cer-
vical cancer [41].
None of the combinations of the polymorphisms had
any significant association with any other parameters in
the control group suggesting the combined risks of the
polymorphisms are not associated with smoking, high-
risk HPV infection and abnormal cytology status in the
larger South-African female population.
Conclusions
The present study showed a reduced risk to cervical can-
cer combining CASP8 -652 6 N del with FasR-670 A al-
lele (P = 0.019, CPS = −2.34) and a marginal susceptible
risk to cervical cancer with CASP8 -652 6 N ins + FasR-
1377G (P = 0.047, CPS = 1.99), only in black Africans.
This study also showed a reduced risk to HSV-2 infec-
tion with CASP8 -652 6 N ins + FasR-1377A in the con-
trol group. The results must be interpreted cautiously.
This was a sub-group analysis of our original study and
the results could be influenced due to several possible
population or biological confounding factors that are
hitherto unrecognized. Future studies on larger cohorts
are warranted to further confirm these findings and to
elucidate the mechanisms involved.
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